Aminase, a patented blend of proteolytic enzymes, is primarily used in Protein-Energy Wasting (PEW) and Protein-Energy Malnutrition (PEM) associated with conditions such as Chronic Kidney Disease (CKD), Liver Cirrhosis, Cancer Cachexia, Chronic Obstructive Pulmonary Disease (COPD), and Tuberculosis (TB) to promote skeletal mass buildup.
Aminase also serves as a potential therapy for addressing Anorexia. It exhibits the capability to balance the Grehlin and Leptin hormones, presenting a promising solution in the treatment of Anorexia.
Yes, Aminase is classified under the Generally Recognized as Safe (GRAS) category. The enzymes in Aminase are derived from a microbial source, and their long-term safety has been established through clinical trials.
Here are the transformative benefits of Aminase:
Explore the compelling scientific data backing Aminase, shedding light on its efficacy in addressing protein energy wasting in end-stage kidney disease and its impact on hemodialysis patients, as published in reputable journals:
To prevent severe gastrointestinal discomfort, always take Aminase immediately after having a protein-rich meal, and avoid taking it on an empty stomach.
Aminase is packaged in boxes containing 28 capsules each and should be stored in a refrigerator at temperatures ranging from 2-25 degrees Celsius. However, if kept outside for a brief period, not exceeding 2-3 days (while strictly avoiding exposure to sunlight), the product remains stable.
Yes, Aminase has been granted a patent.